The growth factor receptors EGFR and c-Met are widely expressed on cancer cells and are implicated in the development and progression of many tumor types through multiple effects on cell cycle progression, apoptosis, and invasion, using a highly overlapping repertoire of signalling adaptors and downstream pathways. However, EGFR and Met inhibitors have been approved only for a limited number of malignancies, and further studies to evaluate novel applications, as well as identify biomarkers to guide these treatments are warranted. Similarly, new drug combinations might represent a major strategy to overcome the reasons of their failures, such as inherent or acquired resistance, in different tumors. Therefore, this special issue will provide the readers working in basic biomedical sciences as well as clinicians a comprehensive overview of novel compounds interacting with EGFR and c-Met, with the aim of clarifying their development, pharmacology, resistance factors, and new therapeutic strategies against major solid tumors.
